Literature DB >> 9486987

Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity.

H Laine1, H Yki-Jarvinen, O Kirvela, T Tolvanen, M Raitakari, O Solin, M Haaparanta, J Knuuti, P Nuutila.   

Abstract

We tested the hypothesis that endothelium-dependent vasodilatation is a determinant of insulin resistance of skeletal muscle glucose uptake in human obesity. Eight obese (age 26+/-1 yr, body mass index 37+/-1 kg/m2) and seven nonobese males (25+/-2 yr, 23+/-1 kg/m2) received an infusion of bradykinin into the femoral artery of one leg under intravenously maintained normoglycemic hyperinsulinemic conditions. Blood flow was measured simultaneously in the bradykinin and insulin- and the insulin-infused leg before and during hyperinsulinemia using [15O]-labeled water ([15O]H2O) and positron emission tomography (PET). Glucose uptake was quantitated immediately thereafter in both legs using [18F]- fluoro-deoxy-glucose ([18F]FDG) and PET. Whole body insulin-stimulated glucose uptake was lower in the obese (507+/-47 mumol/m2 . min) than the nonobese (1205+/-97 micromol/m2 . min, P < 0.001) subjects. Muscle glucose uptake in the insulin-infused leg was 66% lower in the obese (19+/-4 micromol/kg muscle . min) than in the nonobese (56+/-9 micromol/kg muscle . min, P < 0.005) subjects. Bradykinin increased blood flow during hyperinsulinemia in the obese subjects by 75% from 16+/-1 to 28+/-4 ml/kg muscle . min (P < 0.05), and in the normal subjects by 65% from 23+/-3 to 38+/-9 ml/kg muscle . min (P < 0.05). However, this flow increase required twice as much bradykinin in the obese (51+/-3 microg over 100 min) than in the normal (25+/-1 mug, P < 0.001) subjects. In the obese subjects, blood flow in the bradykinin and insulin-infused leg (28+/-4 ml/kg muscle . min) was comparable to that in the insulin-infused leg in the normal subjects during hyperinsulinemia (24+/-5 ml/kg muscle . min). Despite this, insulin-stimulated glucose uptake remained unchanged in the bradykinin and insulin-infused leg (18+/-4 mumol/kg . min) compared with the insulin-infused leg (19+/-4 micromol/kg muscle . min) in the obese subjects. Insulin-stimulated glucose uptake also was unaffected by bradykinin in the normal subjects (58+/-10 vs. 56+/-9 micromol/kg . min, bradykinin and insulin versus insulin leg). These data demonstrate that obesity is characterized by two distinct defects in skeletal muscle: insulin resistance of cellular glucose extraction and impaired endothelium-dependent vasodilatation. Since a 75% increase in blood flow does not alter glucose uptake, insulin resistance in obesity cannot be overcome by normalizing muscle blood flow.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9486987      PMCID: PMC508668          DOI: 10.1172/JCI1065

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Forearm metabolism in obesity and its response to intra-arterial insulin. Characterization of insulin resistance and evidence for adaptive hyperinsulinism.

Authors:  D RABINOWITZ; K L ZIERLER
Journal:  J Clin Invest       Date:  1962-12       Impact factor: 14.808

2.  Forearm glucose uptake during the oral glucose tolerance test in normal subjects.

Authors:  R A Jackson; N Peters; U Advani; G Perry; J Rogers; W H Brough; T R Pilkington
Journal:  Diabetes       Date:  1973-06       Impact factor: 9.461

3.  Quantitative blood flow measurement of skeletal muscle using oxygen-15-water and PET.

Authors:  U Ruotsalainen; M Raitakari; P Nuutila; V Oikonen; H Sipilä; M Teräs; M J Knuuti; P M Bloomfield; H Iida
Journal:  J Nucl Med       Date:  1997-02       Impact factor: 10.057

4.  Evidence that nitric oxide increases glucose transport in skeletal muscle.

Authors:  T W Balon; J L Nadler
Journal:  J Appl Physiol (1985)       Date:  1997-01

5.  Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma.

Authors:  B Zhang; J Berger; G Zhou; A Elbrecht; S Biswas; S White-Carrington; D Szalkowski; D E Moller
Journal:  J Biol Chem       Date:  1996-12-13       Impact factor: 5.157

6.  Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance.

Authors:  H O Steinberg; H Chaker; R Leaming; A Johnson; G Brechtel; A D Baron
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

7.  Inhibition of oxidation of low density lipoprotein by troglitazone.

Authors:  N Noguchi; H Sakai; Y Kato; J Tsuchiya; Y Yamamoto; E Niki; H Horikoshi; T Kodama
Journal:  Atherosclerosis       Date:  1996-06       Impact factor: 5.162

8.  Role of blood flow in regulating insulin-stimulated glucose uptake in humans. Studies using bradykinin, [15O]water, and [18F]fluoro-deoxy-glucose and positron emission tomography.

Authors:  P Nuutila; M Raitakari; H Laine; O Kirvelä; T Takala; T Utriainen; S Mäkimattila; O P Pitkänen; U Ruotsalainen; H Iida; J Knuuti; H Yki-Järvinen
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

9.  Interaction of carbohydrate and fat fuels in human skeletal muscle: impact of obesity and NIDDM.

Authors:  L J Mandarino; A Consoli; A Jain; D E Kelley
Journal:  Am J Physiol       Date:  1996-03

10.  Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects.

Authors:  K A Jamerson; S D Nesbitt; J V Amerena; E Grant; S Julius
Journal:  Hypertension       Date:  1996-04       Impact factor: 10.190

View more
  21 in total

1.  Dynamic PET imaging reveals heterogeneity of skeletal muscle insulin resistance.

Authors:  Jason M Ng; Alessandra Bertoldo; Davneet S Minhas; Nicole L Helbling; Paul M Coen; Julie C Price; Claudio Cobelli; David E Kelley; Bret H Goodpaster
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

2.  Endothelial dysfunction in type 2 diabetes.

Authors:  A Natali; E Ferrannini
Journal:  Diabetologia       Date:  2012-01-20       Impact factor: 10.122

Review 3.  Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature.

Authors:  Eugene J Barrett; Hong Wang; Charles T Upchurch; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-05-24       Impact factor: 4.310

4.  Antiobesogenic role of endothelial nitric oxide synthase.

Authors:  Brian E Sansbury; Bradford G Hill
Journal:  Vitam Horm       Date:  2014       Impact factor: 3.421

Review 5.  The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action.

Authors:  E J Barrett; E M Eggleston; A C Inyard; H Wang; G Li; W Chai; Z Liu
Journal:  Diabetologia       Date:  2009-03-13       Impact factor: 10.122

Review 6.  The IGF-1 receptor and regulation of nitric oxide bioavailability and insulin signalling in the endothelium.

Authors:  V Kate Gatenby; Helen Imrie; Mark Kearney
Journal:  Pflugers Arch       Date:  2013-01-22       Impact factor: 3.657

7.  Endogenous nitric oxide contributes to bradykinin-stimulated glucose uptake but attenuates vascular tissue-type plasminogen activator release.

Authors:  Mias Pretorius; Nancy J Brown
Journal:  J Pharmacol Exp Ther       Date:  2009-10-19       Impact factor: 4.030

8.  Extracellular superoxide dismutase is a growth regulatory mediator of tissue injury recovery.

Authors:  Juha P Laurila; Maria D Castellone; Antonio Curcio; Lilja E Laatikainen; Merja Haaparanta-Solin; Tove J Gronroos; Paivi Marjamaki; Satu Martikainen; Massimo Santoro; Mikko O Laukkanen
Journal:  Mol Ther       Date:  2008-12-23       Impact factor: 11.454

9.  Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects.

Authors:  Michael P Dubé; Jude Christopher Gorski; Changyu Shen
Journal:  Cardiovasc Toxicol       Date:  2008-01-03       Impact factor: 3.231

Review 10.  The sweeter side of ACE2: physiological evidence for a role in diabetes.

Authors:  Sharell M Bindom; Eric Lazartigues
Journal:  Mol Cell Endocrinol       Date:  2008-10-01       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.